UBS Group’s CureVac CVAC Stock Holding History

UBS Group’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-110,000	Closed	-$8.08M	–	9614
2021 Q2	$8.08M	Buy	+110,000	New	+$11M	﹤0.01%	2221

UBS Group's CVAC Position: Q1 2026 in Review

UBS Group sold out of CureVac (CVAC) in Q1 2026, closing a stake of 64,879 shares — an estimated $293K sold.

UBS Group first reported a position in CVAC in Q3 2020 and held it in 22 quarters. The position peaked at $8.35M in Q2 2021. 0 funds tracked by Wall St. Rank hold CVAC as of Q1 2026.

UBS Group reported no remaining CureVac position as of Q1 2026 after selling out during the quarter.
UBS Group sold 64,879 CureVac shares in Q1 2026, an estimated $293K.
UBS Group first reported a position in CureVac in Q3 2020 and held it in 22 quarters.
UBS Group's CureVac position peaked at $8.35M in Q2 2021.
0 funds tracked by Wall St. Rank held CureVac as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.